The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 9th 2024
Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Predicting Fracture Risk in Patients with Osteoporosis
In 2014, the fracture risk algorithm FRAX celebrated its 20-year anniversary. Developed by a World Health Organization (WHO) study group in 1994, FRAX is a freely available diagnostic tool used to evaluate the 10-year probability of bone fracture risk, mostly for patients with osteoporosis. It is a part of many national health guidelines worldwide.
Plasma Exchange May Be Effective Treatment for CRPS
Complex regional pain syndrome (CRPS) is one of the pain conditions that has remained fairly mysterious, but a new, effective treatment may be on the horizon. It is known that CRPS most often develops following trauma, however, and evidence suggests a maladaptive response to nervous system damage involving immune and inflammatory pathways as well as abnormalities in both peripheral and central processing of afferent inputs. No single therapy – including pharmacologic therapy – wholly addresses the condition.
DMARD-Free Sustained Remission in Rheumatoid Arthritis with Early and Intense Treatment
Rheumatoid arthritis therapy that focuses on early and more intensive treatment produces DMARD-free sustained remission, according to findings from researchers at the Karolinska Institutet.
Two Extra Minutes for Medication Safety?
As the population ages and medicine continues to advance, people are living longer and healthier; but they are also taking more medications for more medical conditions. Those medications can cause drug-drug interactions that lead to adverse drug reactions (ADR). Studies have shown that the majority of medication errors happen at the stage of prescription.
Psoriatic Arthritis: How it Stacks up to Rheumatoid Arthritis and Psoriasis
August 10th 2015Inflammatory rheumatic diseases have long been associated with increased morbidity and mortality. A new study compares the prevalence of comorbidities among psoriatic arthritis, rheumatoid arthritis and psoriasis.
Land Down Under Undertreats Gout
Despite a number of effective medication therapy options, there is international evidence that gout is inadequately treated. Studies in the United States, the United Kingdom, and now Australia, show the same triad of ineffectiveness: low levels of urate-lowering therapy (ULT), infrequent serum urate and renal function testing, and very low rates of achievement of target serum urate levels.
New Evidence Points to Potential Biomarker for Giant Cell Arteritis
Advances in genomic study are enabling researchers to narrow down the specific alleles that may contribute most heavily to the epigenetic reasons behind giant cell arteritis and other rheumatic conditions.
After House Passage 21st Century Cures Act Awaits Senate Approval
With funding meant to bolster basic research and help make advances for a variety of conditions the fate of the 21st Century Cure Act is anything but secure even after passage by the US House of Representatives.
Patients with Psoriatic Arthritis at Higher Risk for Uveitis
Researchers found that not only are patients with psoriasis or psoriatic arthritis at higher risk for uveitis, the association is bidirectional: patients with uveitis are at increased risk for psoriasis and psoriatic arthritis
High Energy Exercise May Improve Cardiovascular Health in Patients with Arthritis
July 30th 2015Although many patients with arthritis have a difficult time engaging in high-intensity exercises, that may be the very thing they need to reduce their risk for cardiovascular complications associated with the disease.
10-Year Follow-up Study on Safety and Efficacy of Adalimumab
Study shows that adalimumab led to sustained clinical and functional responses in nearly one-third of treatment-refractory patients who completed 10 years of treatment. Patients with shorter disease duration achieved better outcomes, highlighting the need for early treatment.
IL-Targeted Biologics for Treatment of Psoriasis Show Promising Efficacy
A recent review looked at the immunopathogenesis of psoriasis, identified key mediators of psoriatic plaques that are being targeted by new and emerging biologic therapies, and highlighted the latest efficacy and safety data from trials of these new agents.